Karyopharm Therapeutics (KPTI) Competitors $7.68 -0.13 (-1.66%) Closing price 08/28/2025 04:00 PM EasternExtended Trading$7.82 +0.14 (+1.77%) As of 08/28/2025 06:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KPTI vs. HRTX, LYEL, ACRS, IPHA, VTYX, TRDA, GNFT, MDWD, RAPT, and NLTXShould you be buying Karyopharm Therapeutics stock or one of its competitors? The main competitors of Karyopharm Therapeutics include Heron Therapeutics (HRTX), Lyell Immunopharma (LYEL), Aclaris Therapeutics (ACRS), Innate Pharma (IPHA), Ventyx Biosciences (VTYX), Entrada Therapeutics (TRDA), GENFIT (GNFT), MediWound (MDWD), Rapt Therapeutics (RAPT), and Neoleukin Therapeutics (NLTX). These companies are all part of the "pharmaceutical products" industry. Karyopharm Therapeutics vs. Its Competitors Heron Therapeutics Lyell Immunopharma Aclaris Therapeutics Innate Pharma Ventyx Biosciences Entrada Therapeutics GENFIT MediWound Rapt Therapeutics Neoleukin Therapeutics Karyopharm Therapeutics (NASDAQ:KPTI) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment and analyst recommendations. Do institutionals & insiders hold more shares of KPTI or HRTX? 66.4% of Karyopharm Therapeutics shares are owned by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are owned by institutional investors. 3.0% of Karyopharm Therapeutics shares are owned by insiders. Comparatively, 5.9% of Heron Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has stronger earnings & valuation, KPTI or HRTX? Heron Therapeutics has lower revenue, but higher earnings than Karyopharm Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKaryopharm Therapeutics$145.24M0.46-$76.42M-$14.59-0.53Heron Therapeutics$144.29M1.48-$13.58M-$0.02-69.50 Does the media refer more to KPTI or HRTX? In the previous week, Karyopharm Therapeutics and Karyopharm Therapeutics both had 3 articles in the media. Karyopharm Therapeutics' average media sentiment score of 1.14 beat Heron Therapeutics' score of 1.11 indicating that Karyopharm Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Karyopharm Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Heron Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is KPTI or HRTX more profitable? Heron Therapeutics has a net margin of -0.62% compared to Karyopharm Therapeutics' net margin of -90.02%. Company Net Margins Return on Equity Return on Assets Karyopharm Therapeutics-90.02% N/A -84.28% Heron Therapeutics -0.62%N/A -0.40% Do analysts recommend KPTI or HRTX? Karyopharm Therapeutics currently has a consensus price target of $34.00, suggesting a potential upside of 342.71%. Heron Therapeutics has a consensus price target of $4.50, suggesting a potential upside of 223.74%. Given Karyopharm Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Karyopharm Therapeutics is more favorable than Heron Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Karyopharm Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Heron Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Which has more risk & volatility, KPTI or HRTX? Karyopharm Therapeutics has a beta of 0.28, suggesting that its stock price is 72% less volatile than the S&P 500. Comparatively, Heron Therapeutics has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500. SummaryHeron Therapeutics beats Karyopharm Therapeutics on 8 of the 14 factors compared between the two stocks. Get Karyopharm Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KPTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KPTI vs. The Competition Export to ExcelMetricKaryopharm TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$67.72M$2.51B$5.78B$9.79BDividend YieldN/A1.68%3.95%4.02%P/E Ratio-0.5322.8231.2626.59Price / Sales0.46539.52431.16158.34Price / CashN/A177.0937.7359.36Price / Book-0.286.1810.046.68Net Income-$76.42M$32.94M$3.27B$265.59M7 Day Performance21.90%-0.78%1.34%0.66%1 Month Performance85.96%2.77%6.13%2.64%1 Year Performance-33.58%12.01%41.90%22.36% Karyopharm Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KPTIKaryopharm Therapeutics4.0362 of 5 stars$7.68-1.7%$34.00+342.7%-34.5%$67.72M$145.24M-0.53380HRTXHeron Therapeutics4.0696 of 5 stars$1.30-2.3%$4.50+246.2%-28.0%$203.88M$144.29M-65.00300Positive NewsLYELLyell Immunopharma3.7728 of 5 stars$10.89+2.9%$15.00+37.7%-61.7%$203.26M$60K-0.45270ACRSAclaris Therapeutics2.6658 of 5 stars$1.85-1.1%$8.71+371.0%+53.3%$202.58M$18.72M-1.35100IPHAInnate Pharma2.4425 of 5 stars$2.23+1.8%$11.00+393.3%-7.3%$201.88M$21.77M0.00220Negative NewsGap UpVTYXVentyx Biosciences2.5801 of 5 stars$2.83flat$7.50+165.0%+11.4%$201.80MN/A-1.6830TRDAEntrada Therapeutics3.1358 of 5 stars$5.52+4.7%$25.67+365.0%-65.4%$200.46M$210.78M-3.10110Positive NewsGNFTGENFIT1.9605 of 5 stars$4.50+12.8%$13.00+188.9%-4.4%$199.51M$76.77M0.00120Gap DownHigh Trading VolumeMDWDMediWound1.4386 of 5 stars$17.60-2.8%$32.25+83.2%-12.3%$195.62M$20.22M-6.6780RAPTRapt Therapeutics4.4191 of 5 stars$11.73-0.1%$21.57+83.9%-36.9%$194.15M$1.53M-0.8380NLTXNeoleukin TherapeuticsN/A$20.51+1.5%N/A-44.9%$192.75MN/A-6.5990High Trading Volume Related Companies and Tools Related Companies Heron Therapeutics Competitors Lyell Immunopharma Competitors Aclaris Therapeutics Competitors Innate Pharma Competitors Ventyx Biosciences Competitors Entrada Therapeutics Competitors GENFIT Competitors MediWound Competitors Rapt Therapeutics Competitors Neoleukin Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KPTI) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karyopharm Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Karyopharm Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access